Summit Launches Globally Study of Ivonescimab in Bladder Cancer
Summit Therapeutics announced the HARMONi-GU1 Phase II/III trial for ivonescimab in first-line bladder cancer. The study targets a major indication for ii antibodies in oncology.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day